TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15839828

Group type: EXPERIMENTAL
Intervention: Intraligamental local analgesia (ILA) with bupivicaine 0.5% and 1:200,000 adrenaline
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Intraligamental local analgesia (ILA)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control side (no ILA)
Number of subjects: 30
Study: 14759321

Group type: EXPERIMENTAL
Intervention: Ceftriaxone (50 mg/kg, total dose < 1 g) injected once
Number of subjects: 236

Group type: COMPARATOR
Intervention: Amoxicillin (40 mg/(kg.d), tid) for 10 days
Number of subjects: 236
Study: 10233203

Group type: COMPARATOR
Intervention: 200 mg racemic ibuprofen
Number of subjects: 14

Group type: COMPARATOR
Intervention: 600 mg racemic ibuprofen
Number of subjects: 14
Study: 8942221

Group type: EXPERIMENTAL
Intervention: Cefuroxime (750 mg i.v. 8H for 48 H/500 mg p.o bid)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Amoxicillin-clavulanic acid (1.2 g i.v. 8 H for 48 H/750 mg p.o. tid)
Number of subjects: 48
Study: 1763562

Group type: EXPERIMENTAL
Intervention: Preparation A (microspheres of size 1.0-1.2 mm)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Preparation B (microspheres of size 1.8-2.0 mm)
Number of subjects: 10
Study: 6215932

Group type: EXPERIMENTAL
Intervention: Halothane
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Enflurane
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Isoflurane
Number of subjects: 75
Study: 30742596

Group type: EXPERIMENTAL
Intervention: Tissue Preservation Technique
Number of subjects: 25

Group type: COMPARATOR
Intervention: Tissue Reduction Technique
Number of subjects: 25
Study: 28657133

Group type: EXPERIMENTAL
Intervention: Alcohol-free CHX mouthrinse
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: CHX with antidiscoloration system (CHX-ADS)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (metal-stainless steel brackets)
Number of subjects: 80
Study: 26479856

Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Moderate-Intensity Continuous Training (MICT)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Short-Duration High-Intensity Interval Training (1/2HIIT)
Number of subjects: 46
Study: 24755007

Group type: EXPERIMENTAL
Intervention: BARC Type 2, 3, or 5 bleeding
Number of subjects: 2000

Group type: EXPERIMENTAL
Intervention: BARC Type 3 or 5 bleeding
Number of subjects: 2000

Group type: EXPERIMENTAL
Intervention: TIMI criteria
Number of subjects: 2000

Group type: EXPERIMENTAL
Intervention: GUSTO criteria
Number of subjects: 2000

Group type: EXPERIMENTAL
Intervention: Overall mortality
Number of subjects: 2000
Study: 22678699

Group type: EXPERIMENTAL
Intervention: S-adenosyl-L-methionine (SAMe) 800 mg bid for 6 weeks
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: S-adenosyl-L-methionine (SAMe)
Number of subjects: 12
Study: 20515432

Group type: COMPARATOR
Intervention: Internal fixation
Number of subjects: 222

Group type: EXPERIMENTAL
Intervention: Hemiarthroplasty
Number of subjects: 222
Study: 17986636

Group type: EXPERIMENTAL
Intervention: PF-00915275 (15 mg)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: PF-00915275 (0.3-15 mg)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 15664001

Group type: EXPERIMENTAL
Intervention: Intranasal salmon calcitonin therapy (200 IU nasal spray daily during alternate months) + 400 IU Vitamin D + 1000 mg elemental calcium
Number of subjects: 71
Study: 11799482

Group type: EXPERIMENTAL
Intervention: Temporary portacaval shunt during the anhepatic phase
Number of subjects: 40

Group type: COMPARATOR
Intervention: No temporary portacaval shunt
Number of subjects: 40
Study: 10583020

Group type: EXPERIMENTAL
Intervention: Lorazepam 2 mg oral dose
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 8700255

Group type: EXPERIMENTAL
Intervention: Shared governance implementation
Number of subjects: 0
Study: 1930053

Group type: EXPERIMENTAL
Intervention: Dexamethasone (4 mg every 6 h)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 7091469

Group type: EXPERIMENTAL
Intervention: Smoker/nonsmoker segregation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no segregation)
Number of subjects: 0
Study: 31996652

Group type: EXPERIMENTAL
Intervention: CT‐GFR with iohexol 240
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: CT‐GFR with iobitridol 400
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: CT‐GFR at the renal cortex
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Whole‐kidney CT‐GFR at ≥80 seconds after CM appearance
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: CT‐GFR calculated using perfusion CT software with strong noise reduction
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: CT‐GFR calculated using perfusion software with medium noise reduction
Number of subjects: 100
Study: 28741660

Group type: EXPERIMENTAL
Intervention: Imitative behavior of human children
Number of subjects: 77

Group type: COMPARATOR
Intervention: Imitative behavior of bonobos
Number of subjects: 77
Study: 26845453

Group type: EXPERIMENTAL
Intervention: Normoxia (Pdi,twc assessment every 45 s)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Normobaric hypoxia (SpO2 80%, Pdi,twc assessment every 45 s)
Number of subjects: 17
Study: 25466568

Group type: EXPERIMENTAL
Intervention: CCTA (dual-source CT angiography)
Number of subjects: 562

Group type: COMPARATOR
Intervention: ExECG (exercise stress ECG)
Number of subjects: 562
Study: 22014374

Group type: EXPERIMENTAL
Intervention: Malaria, pathogenic protozoan and hookworm infections at baseline
Number of subjects: 904

Group type: EXPERIMENTAL
Intervention: Low baseline vitamin D (<32 ng/ml) concentrations
Number of subjects: 904

Group type: EXPERIMENTAL
Intervention: Higher baseline erythrocyte sedimentation rate and CD8 T-cell concentrations, lower Hb concentrations and CD4 T-cell counts
Number of subjects: 904
Study: 20524441

Group type: EXPERIMENTAL
Intervention: Microdebrider-assisted intracapsular tonsillectomy (MT)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Cold instrument dissection tonsillectomy (CT)
Number of subjects: 40
Study: 16905572

Group type: EXPERIMENTAL
Intervention: Oestradiol (2.5 mg/kg/day) and progesterone (22.5 mg/kg/day) given by continuous intravenous infusion of a standard lipid emulsion (15 ml/kg/day)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Placebo (same lipid emulsion without oestradiol or progesterone)
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Oestradiol and progesterone (according to protocol)
Number of subjects: 83
Study: 16244006

Group type: EXPERIMENTAL
Intervention: Gabapentin, eutectic mixture of local anesthetics cream, and ropivacaine in the wound
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (placebos)
Number of subjects: 50
Study: 11952769

Group type: EXPERIMENTAL
Intervention: Tiagabine (TGB; Gabitril) 32 or 56 mg daily
Number of subjects: 554

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 554
Study: 10374370

Group type: EXPERIMENTAL
Intervention: Artemether (Art) - 6 mg/kg, administered every 15 days if continued exposure, with an additional dose 7-15 days after withdrawal from pilot.
Number of subjects: 99

Group type: COMPARATOR
Intervention: Placebo (starch)
Number of subjects: 99
Study: 7667188

Group type: EXPERIMENTAL
Intervention: u‐hFSH 75 IU iv
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: u‐hFSH 150 IU iv
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: u‐hFSH 300 IU iv
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: u‐hFSH 150 IU im
Number of subjects: 12
Study: 2765151

Group type: EXPERIMENTAL
Intervention: Op-site dressing
Number of subjects: 0

Group type: COMPARATOR
Intervention: Other treatment methods
Number of subjects: 0
Study: 1102887

Group type: EXPERIMENTAL
Intervention: Trivastal (1 dragee daily, increasing to 3-6 dragees over 14 weeks)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study: 31226197

Group type: EXPERIMENTAL
Intervention: Periodontally Accelerated Osteogenic Orthodontics (PAOO) followed by orthodontic fixed mechanotherapy
Number of subjects: 2

Group type: COMPARATOR
Intervention: Orthodontic fixed mechanotherapy alone
Number of subjects: 2
Study: 27416014

Group type: EXPERIMENTAL
Intervention: Dance intervention
Number of subjects: 112
Study: 25039499

Group type: EXPERIMENTAL
Intervention: Mean Transit Time (MTT) thresholds of ≥ 7 seconds
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Relative MTT thresholds of ≥ 125%
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Delay Time (DT) thresholds of ≥ 2 seconds
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Absolute MTT thresholds of 8 seconds
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Relative MTT thresholds of 125%
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Relative Cerebral Blood Flow (CBF) thresholds of ≤ 45%
Number of subjects: 0
Study: 22662394

Group type: EXPERIMENTAL
Intervention: Psychotherapy interventions
Number of subjects: 105

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 105
Study: 20837359

Group type: COMPARATOR
Intervention: Paclitaxel + cisplatin (PC)
Number of subjects: 434

Group type: EXPERIMENTAL
Intervention: Vinorelbine + cisplatin (VC)
Number of subjects: 434

Group type: EXPERIMENTAL
Intervention: Gemcitabine + cisplatin (GC)
Number of subjects: 434

Group type: EXPERIMENTAL
Intervention: Topotecan + cisplatin (TC)
Number of subjects: 434
Study: 19041475

Group type: EXPERIMENTAL
Intervention: Epi-LASIK
Number of subjects: 56

Group type: COMPARATOR
Intervention: off-flap Epi-LASIK
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Epi-LASIK and off-flap Epi-LASIK
Number of subjects: 56
Study: 16626422

Group type: EXPERIMENTAL
Intervention: Conjunctival impression cytology in group 1 (PEXG)
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Conjunctival impression cytology in group 2 (PEX)
Number of subjects: 143

Group type: COMPARATOR
Intervention: Conjunctival impression cytology in group 3 (normal subjects)
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Tear film break-up time (TFBUT) in group 1 (PEXG)
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Tear film break-up time (TFBUT) in group 2 (PEX)
Number of subjects: 143

Group type: COMPARATOR
Intervention: Tear film break-up time (TFBUT) in group 3 (normal subjects)
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Basal Schirmer test (BST) in group 1 (PEXG)
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Basal Schirmer test (BST) in group 2 (PEX)
Number of subjects: 143

Group type: COMPARATOR
Intervention: Basal Schirmer test (BST) in group 3 (normal subjects)
Number of subjects: 143
Study: 12823236

Group type: EXPERIMENTAL
Intervention: Initial OGTT 2-hour blood glucose level
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Subscapular skinfold thickness
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Subscapular skinfold thickness after adjustment for 2-hour blood glucose levels
Number of subjects: 108
Study: 10967266

Group type: EXPERIMENTAL
Intervention: Antiresorptive therapy (30 mg pamidronate IV every 3 months, n = 14)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Calcium and vitamin D supplementation (n = 10)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Hormonal replacement therapy (n = 5)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Antiresorptive therapy (pamidronate or HRT)
Number of subjects: 42
Study: 8829118

Group type: EXPERIMENTAL
Intervention: Dopamine infusion alone
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Furosemide infusion alone
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Furosemide and dopamine infusions administered concurrently
Number of subjects: 8

Group type: COMPARATOR
Intervention: Dopamine, Furosemide, or their coadministration
Number of subjects: 8
Study: 7949627

Group type: EXPERIMENTAL
Intervention: TBARM in ALI patients (3.05 +/‐ 0.65 nMol/ml)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: 7S collagen in ALI patients (9.06 +/‐ 5.96 ng/ml)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: TBARM levels in deceased ALI patients
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: 7S collagen levels in deceased ALI patients
Number of subjects: 21
Study: 3228992

Group type: EXPERIMENTAL
Intervention: Local Anaesthetic (LA)
Number of subjects: 29

Group type: COMPARATOR
Intervention: General Anaesthetic (GA)
Number of subjects: 29
Study: 30476603

Group type: EXPERIMENTAL
Intervention: Treadmill CPET
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Bike CPET
Number of subjects: 24
Study: 28869989

Group type: EXPERIMENTAL
Intervention: Prostate cancer screening
Number of subjects: 2

Group type: COMPARATOR
Intervention: No screening
Number of subjects: 2
Study: 27045252

Group type: EXPERIMENTAL
Intervention: Limaprost
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pregabalin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Limaprost + Pregabalin
Number of subjects: 0
Study: 23386159

Group type: EXPERIMENTAL
Intervention: Intraperitoneal (IP) bupivacaine
Number of subjects: 48

Group type: COMPARATOR
Intervention: Intravenous (IV) pethidine
Number of subjects: 48
Study: 20959965

Group type: EXPERIMENTAL
Intervention: Multifactorial evaluation and treatment of fall risk factors
Number of subjects: 217

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 217
Study: 19448228

Group type: EXPERIMENTAL
Intervention: Lidocaine patch
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study: 17098764

Group type: EXPERIMENTAL
Intervention: 40 mg simvastatin daily
Number of subjects: 20536
Study: 15659895

Group type: EXPERIMENTAL
Intervention: 24F Re‐entry tube
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 8F pigtail catheter
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Double‐J stent
Number of subjects: 60
Study: 11443565

Group type: EXPERIMENTAL
Intervention: HIV-1 load 2 years after seroconversion
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Change over time (slope) of HIV-1 load
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Early virus loads
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Slopes of virus load
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Higher early virus loads
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Higher slopes of virus load
Number of subjects: 22
Study: 9118614

Group type: EXPERIMENTAL
Intervention: GM-CSF 300 U/d on days 8 and 15 post-chemotherapy for neutropenia prophylaxis
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control group (no GM-CSF)
Number of subjects: 34
Study: 1999086

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 300 mg i.v. every 12 hours for pneumonia
Number of subjects: 31

Group type: COMPARATOR
Intervention: Ceftazidime 2 g i.v. every eight hours for pneumonia
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 200 mg i.v. every 12 hours for UTI
Number of subjects: 31

Group type: COMPARATOR
Intervention: Ceftazidime 1 g i.v. every eight hours for UTI
Number of subjects: 31
Study: 6465021

Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Verapamil
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 31690602

Group type: EXPERIMENTAL
Intervention: Supervised exercise training (2-year duration, 2 weekly sessions: 5 min warm-up, 20 min aerobic training, 30 min resistance training, 20 min core stability, balance and flexibility training with weighted vests)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Supervised exercise training
Number of subjects: 200
Study: 28743399

Group type: EXPERIMENTAL
Intervention: Educational intervention (three educational sessions)
Number of subjects: 320

Group type: COMPARATOR
Intervention: Control group (informative leaflet)
Number of subjects: 320
Study: 25746777

Group type: EXPERIMENTAL
Intervention: self‐administered mCBT‐I (n=20; 6 short booklets + 3 phone consultations with a psychologist, over 6 weeks)
Number of subjects: 38

Group type: COMPARATOR
Intervention: no‐treatment condition (n=18)
Number of subjects: 38
Study: 23403498

Group type: EXPERIMENTAL
Intervention: Alendronate (10 mg/d) with hormone therapy (HT)
Number of subjects: 139

Group type: COMPARATOR
Intervention: Placebo with hormone therapy (HT)
Number of subjects: 139
Study: 21788220

Group type: EXPERIMENTAL
Intervention: Propranolol hydrochloride 2 mg/kg per day divided 3 times daily for 6 months
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo oral solution
Number of subjects: 40
Study: 19019932

Group type: EXPERIMENTAL
Intervention: Travoprost/timolol maleate fixed combination (TTFC)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Travoprost
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 32
Study: 17569958

Group type: EXPERIMENTAL
Intervention: MDCTA
Number of subjects: 237

Group type: COMPARATOR
Intervention: US‐ECD
Number of subjects: 237
Study: 15007574

Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin G
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 11172508

Group type: COMPARATOR
Intervention: Lateral decubitus position (group I)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Prone position (group II)
Number of subjects: 70
Study: 9728835

Group type: EXPERIMENTAL
Intervention: Intrathecal clonidine 150 microg
Number of subjects: 16

Group type: COMPARATOR
Intervention: Intravenous clonidine 50 or 150 microg
Number of subjects: 16
Study: 8899390

Group type: EXPERIMENTAL
Intervention: Severe obesity (defined using national criteria for severely elevated body mass index)
Number of subjects: 224

Group type: COMPARATOR
Intervention: Control group (matched controls)
Number of subjects: 224
Study: 2626517

Group type: EXPERIMENTAL
Intervention: Placebo condition
Number of subjects: 16

Group type: COMPARATOR
Intervention: Naloxone condition
Number of subjects: 16
Study: 795439

Group type: EXPERIMENTAL
Intervention: Dexatopic ointment (17 beta‐hydroxy‐4‐estren‐3‐one‐17‐decanoate)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Reference ointment
Number of subjects: 81
Study: 31475597

Group type: EXPERIMENTAL
Intervention: Cut umbilical cord milking (C‐UCM)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Intact umbilical cord milking (I‐UCM)
Number of subjects: 62
Study: 31628586

Group type: EXPERIMENTAL
Intervention: L-carnitine (500-mg tablet, 2-3 times daily)
Number of subjects: 42
Study: 31675599

Group type: EXPERIMENTAL
Intervention: Dynamic orthosis
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Static orthosis
Number of subjects: 24

Group type: COMPARATOR
Intervention: Both orthoses
Number of subjects: 24
Study: 28981445

Group type: EXPERIMENTAL
Intervention: Honey cream
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Phenytoin cream
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo cream
Number of subjects: 120

Group type: COMPARATOR
Intervention: All groups (Honey, Phenytoin, Placebo)
Number of subjects: 120
Study: 25678778

Group type: EXPERIMENTAL
Intervention: FDC of gemigliptin/metformin 25/500 mg
Number of subjects: 28

Group type: COMPARATOR
Intervention: Separate tablets of gemigliptin (50 mg) and metformin XR (500 mg)
Number of subjects: 28
Study: 23470575

Group type: EXPERIMENTAL
Intervention: Chewing gum 4 times a day postoperatively
Number of subjects: 161

Group type: COMPARATOR
Intervention: Control group (standard postoperative feeding without chewing gum)
Number of subjects: 161
Study: 21563551

Group type: EXPERIMENTAL
Intervention: Olfactory stimulation with 2-phenyl ethyl alcohol
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Trigeminal stimulation with CO2
Number of subjects: 16

Group type: COMPARATOR
Intervention: Early blind subjects
Number of subjects: 16

Group type: COMPARATOR
Intervention: Sighted controls
Number of subjects: 16
Study: 20099536

Group type: EXPERIMENTAL
Intervention: Intensive behavioral treatment
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Self-help program with telephone follow-up
Number of subjects: 89

Group type: COMPARATOR
Intervention: Brief counseling plus information pamphlet
Number of subjects: 89
Study: 16760174

Group type: EXPERIMENTAL
Intervention: Dacarbazine (DTIC) followed by 6‐month treatment with 3 MU thrice weekly of highly purified natural interferon‐alpha (n = 128; arm A)
Number of subjects: 252

Group type: COMPARATOR
Intervention: No adjuvant treatment (n = 124; arm B)
Number of subjects: 252
Study: 15288157

Group type: EXPERIMENTAL
Intervention: Metoprolol CR/XL
Number of subjects: 915
Study: 11297592

Group type: EXPERIMENTAL
Intervention: 300 mg moclobemide for 75 days
Number of subjects: 21

Group type: COMPARATOR
Intervention: Oral fluocortolone (tapered until day 29)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 9709281

Group type: EXPERIMENTAL
Intervention: Screening mammography among women aged 50 to 69 years
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Screening mammography among women aged 40 to 49 years
Number of subjects: 2
Study: 8302147

Group type: COMPARATOR
Intervention: 1% epidural lidocaine with 1:200000 epinephrine (Gp.E)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 15 micrograms/kg alfentanil initially and 7 micrograms/kg on demand intravenously (Gp.A)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 4 micrograms/kg fentanyl initially and 2 micrograms/kg on demand intravenously (Gp.F)
Number of subjects: 60
Study: 2949907

Group type: EXPERIMENTAL
Intervention: Sodium replete state
Number of subjects: 8

Group type: COMPARATOR
Intervention: Sodium deplete state
Number of subjects: 8
Study: 31883426

Group type: EXPERIMENTAL
Intervention: Letermovir
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study: 30497798

Group type: EXPERIMENTAL
Intervention: 150 mg GLA5PR GLARS-NF1 tablet (controlled-release) taken once daily after a high-fat meal (STF treatment)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: 150 mg GLA5PR GLARS-NF1 tablet (controlled-release) taken in an overnight-fasted state (ST treatment)
Number of subjects: 54

Group type: COMPARATOR
Intervention: 75 mg IR capsules taken twice daily (MRF treatment)
Number of subjects: 54
Study: 27329280

Group type: EXPERIMENTAL
Intervention: Zolmitriptan nasal spray 5 mg
Number of subjects: 798

Group type: EXPERIMENTAL
Intervention: Zolmitriptan nasal spray (all doses)
Number of subjects: 798

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 798